BIOA BioAge Labs, Inc.
USHealthcareAs of 2026-07-08 16:00
Why BIOA matters now
BioAge Labs, Inc. (BIOA) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.63 with -3.16% on the session and $889.7M in market capitalization; recent performance reads 1-month +26.88% and YTD +56.99%.
The latest financial table shown here is Q1 2026, with revenue of $2.8M, net income of $-22.3M, and EPS of $-0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.3%.
The latest indexable market news headline is "BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $40.00; recent insider activity includes GARNIER JEAN PIERRE filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.33
P/S
75.80
EV/EBITDA
-6.10
DCF Value
$9.19
FCF Yield
-11.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-985.9%
Net Margin
-871.8%
ROE
-29.4%
ROA
-22.6%
ROIC
-26.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.8M | $-22.3M | $-0.52 |
| Q4 2025 | $3.1M | $-25.9M | $-0.72 |
| FY 2025 | $9.0M | $-80.6M | $-2.24 |
| Q3 2025 | $2.1M | $-20.2M | $-0.56 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$42.20
Target (Median)
$40.00
Target Range
$23.00 - $62.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.95
BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for metabolic illnesses. The company employs a distinctive technology platform alongside specialized human datasets to pinpoint potential drug targets by unraveling the molecular mechanisms underlying the aging process. Their current pipeline features azelaprag, an oral small molecule, which is undergoing Phase 1 clinical trials for obesity. Additionally, BioAge has commenced a Phase 2 clinical trial for azelaprag, investigating its efficacy in combination with tirzepatide for managing obesity specifically in older adults. Another asset under development is BGE-100, an oral, brain-penetrant small molecule designed to act as an NLRP3 antagonist, aiming to address conditions characterized by neuroinflammation. Established in 2015, BioAge Labs, Inc. operates from its headquarters in Richmond, California.